severe COVID-19
[대역어] 심한 코비드 -19
[용어속성] Disease
[용어속성] Disease
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
중증 코로나19 환자에서 회복기 혈장 요법의 효과
530
Published on
Journal: Proceedings of the National Academy of Sciences of [Category] Communicable Disease, COVID-19, SARS,
Journal: Proceedings of the National Academy of Sciences of [Category] Communicable Disease, COVID-19, SARS,
[키워드] Absorption
addition
Antibody titers
antiviral agent
Antiviral agents
approved
C-reactive protein
clinical benefit
Clinical outcome
clinical outcomes
clinical symptom
Clinical symptoms
convalescent plasma
Convalescent plasma therapy
coronavirus disease
Coronavirus disease 2019
COVID-19
criteria
disappearance
Donor
dose
Endpoint
enrolled
feasibility
FIVE
global health
Health
IMPROVE
laboratory parameter
Laboratory parameters
lung lesion
lung lesions
lymphocyte
Lymphocyte count
maintain
median time
Neutralizing
Neutralizing antibodies
neutralizing antibody
Neutralizing antibody titer
neutralizing antibody titers
Novel coronavirus
novel coronavirus disease
optimal dose
oxyhemoglobin
oxyhemoglobin saturation
parameter
Patient
pilot project
primary endpoint
Radiological examinations
randomized trial
Seven
severe adverse effect
severe COVID-19
severe COVID-19 patient
Severe patient
severe patients
Significance
significantly
supportive care
the patient
therapy
transfused
transfusion
Treatment
Treatment outcome
trials
undetectable
Viral
Viral load
Viral RNA
Viremia
[DOI] 10.1073/pnas.2004168117 PMC 바로가기 [Article Type] 530
[DOI] 10.1073/pnas.2004168117 PMC 바로가기 [Article Type] 530
Pathological Role of Angiotensin II in Severe COVID-19
Review Article
[키워드] activated
Activation
acute respiratory distress
angiotensin
Angiotensin II
angiotensin-converting enzyme 2
caused
characterized
clinical picture
Coagulation
Coagulopathy
complex
COVID-19
COVID-19 patients
death
downregulating
Effect
Elderly patient
exaggerated inflammatory response
expressed
Future
impair
increase
increasingly
induce
Inflammation
inflammatory property
Lung injury
manifestation
new coronavirus SARS-CoV-2
Novel coronavirus infection
pathological
Patient
patients
preexisting comorbidities
produced
proportion
prothrombotic state
receptor
reduced
renin–angiotensin system
resulting
role
SARS-CoV-2
Sepsis
severe complication
severe COVID-19
syndrome
target cells
thrombin
Treatment
triggered
Viral load
[DOI] 10.1055/s-0040-1713678 PMC 바로가기 [Article Type] Review Article
[DOI] 10.1055/s-0040-1713678 PMC 바로가기 [Article Type] Review Article
COVID-19 in persons with haematological cancers
Research
[키워드] baseline
cancers
Care
Case fatality rate
caused
cohort study
conducted
confidence
coronavirus
COVID-19
death
Fatality rate
had more
Haematological cancer
Health
hospitalised
identify
interval
Isolation
no significant difference
outcome
outcomes
pandemic
Protective
risk factor
SARS-CoV-2
severe COVID-19
severe disease
solid cancer
subject
Surveillance
with COVID-19
Wuhan, China
[DOI] 10.1038/s41375-020-0836-7 [Article Type] Research
[DOI] 10.1038/s41375-020-0836-7 [Article Type] Research
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
Article
[키워드] “cytokine storm”
acute respiratory distress
acute respiratory syndrome
adaptive
antagonists
anti-inflammatory treatments
antiinflammatory
association
betacoronaviruses
caused
China
coronavirus
COVID-19
Cytokine storm
disease
drug
feature
Host immune response
Hydroxychloroquine
hyperinflammation
IL-1
immune system
Immunity
Inflammation
information
life-threatening
Lower respiratory tract
membrane
nonstructural proteins
Novel coronavirus
nucleocapsid
outcome
pandemic
pathophysiology
Proinflammatory cytokine
responsible
rheumatology
RNA
SARS-CoV-2
severe COVID-19
severe disease
severity
shown
single-stranded positive-sense
Spike protein
structural proteins
syndrome
the cytokine storm
Treatment
viral infection
viral infectivity
Wuhan
[DOI] 10.3906/sag-2004-168 PMC 바로가기 [Article Type] Article
[DOI] 10.3906/sag-2004-168 PMC 바로가기 [Article Type] Article
COVID-19 Drug Discovery Using Intensive Approaches
Review
[키워드] acute respiratory syndrome
Antiviral
antiviral therapy
caused
China
clinical development
clinical trial
coronavirus
coronavirus disease
Coronaviruses
COVID-19
drug
Drug discovery
drug repositioning
Infection
Infectious disease
information
inhibit
mechanism
MERS
Middle East
Pandemics
provide
reported
response
RNA
RNA virus
SARS-CoV-2
severe COVID-19
Spread
standard treatment
strain
Symptoms
syndrome
therapeutic agent
unique
Vaccine
viral replication
while
WHO
World Health Organization
[DOI] 10.3390/ijms21082839 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/ijms21082839 PMC 바로가기 [Article Type] Review
COVID-19 in otolaryngologist practice: a review of current knowledge
Review Article
[키워드] Anosmia
Clinical characteristics
cough
COVID-19
COVID-19 cases
COVID-19 pandemic
COVID-19 patients
database
determine
develop
Diagnosis
disease transmission
Dizziness
dysfunction
Dyspnea
ear
ENT
individuals
infected with SARS-CoV-2
information
knowledge
limit
manifestation
mechanism
molecular
nasal congestion
nose and throat
Olfaction
Otolaryngological manifestations
otolaryngologist
Patient
Potential treatment
provide
Research
respiratory tract
Result
risk
SARS-CoV-2
searched
severe COVID-19
sore throat
surgeon
Symptom
symptoms of COVID-19
Travel
upper
URT
Web of Science
younger patient
[DOI] 10.1007/s00405-020-05968-y PMC 바로가기 [Article Type] Review Article
[DOI] 10.1007/s00405-020-05968-y PMC 바로가기 [Article Type] Review Article
Prognostic value of NT-proBNP in patients with severe COVID-19
중증 코로나19 환자에서 NT-proBNP의 예후 가치
Research
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
analyzed
best
cardiac injury
Case fatality rate
caused
China
coronavirus
coronavirus disease
Coronavirus disease 2019
correlated
COVID-19
cut-off value
defined
enrolled
Factors
Fatality rate
hospitalized patient
hospitalized patients
In-hospital death
independent risk factor
ineligible
information
Injury
International
medical records
N Terminal
NT-proBNP
NT-proBNT
outbreak
outcome
Patient
peptide
potential risk
predicted
Primary outcome
public health emergency
respiratory
Result
risk of death
SARS-CoV-2
sensitivity
severe acute respiratory syndrome Coronavirus
severe COVID-19
severe COVID-19 patient
severe COVID-19 patients
significantly increased
specificity
with COVID-19
[DOI] 10.1186/s12931-020-01352-w PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s12931-020-01352-w PMC 바로가기 [Article Type] Research
Why tocilizumab could be an effective treatment for severe COVID-19?
Commentary
[키워드] acute respiratory distress
acute respiratory distress syndrome (ARDS)
Admission
alveolar
Analysis
ARDS
Autopsy
cause
caused
contribute
COVID-19
COVID-19 patient
died
effective
Gas exchange
high mortality
Host immune response
ICU
IL-6
IL-6 pathway
IL-6 receptor
impede
Inflammatory cytokine storm
inflammatory monocyte
inflammatory storm
intensive care
monoclonal antibody
Mortality
New coronavirus
pathogenic
progressed
public health
Research
Respiratory function
returned
SARS-CoV-2
severe complication
severe COVID-19
severe COVID-19 patients
Severe patient
Spread
suggested
syndrome
T cell
target
temperature
therapeutic
Tocilizumab
Treatment
[DOI] 10.1186/s12967-020-02339-3 PMC 바로가기 [Article Type] Commentary
[DOI] 10.1186/s12967-020-02339-3 PMC 바로가기 [Article Type] Commentary